Published in final edited form as:

Org Biomol Chem. 2014 January 14; 12(2): 330–344. doi:10.1039/c3ob42191k.

Evolution of an Oxidative Dearomatization Enabled Total Synthesis of Vinigrol

Qingliang Yang^b, Cristian Draghici^b, Jon T. Njardarson^a, Fang Li, Brandon R. Smith^a, and Pradipta Das^a

Jon T. Njardarson: njardars@email.arizona.edu

^aDepartment of Chemistry and Biochemistry, University of Arizona, 1306 E. University Blvd., Tucson, AZ 85721, USA. Fax: (+1) 520-621-8407; Tel: (+1) 520 621-0754

^bDepartment of Chemistry and Chemical Biology, Cornell University, Baker Laboratory, Ithaca, NY 14853, USA

Abstract

The evolution of the synthetic strategy resulting in a total synthesis of vinigrol is presented. Oxidative dearomatization/intramolecular Diels-Alder cycloaddition has served as the successful cornerstone for all of the approaches. Extensive radical cyclization efforts to form the tetracyclic core resulted in interesting and surprising reaction outcomes, none of which could be advanced to vinigrol. These cyclization obstacles were successfully overcome by using Heck instead of radical cyclizations. The total synthesis features a trifluoroethyl ether protecting group being used for the first time in organic synthesis. The logic of its selection and the group's importance beyond protecting the C8a hydroxyl group is presented along with a discussion of strategies for its removal. Because of the compact tetracyclic cage the route is built around many unusual reaction observations and solutions have emerged. For example, a first of its kind Grob fragmentation reaction featuring a trifluoroethyl leaving group has been uncovered, interesting interrupted selenium dioxide allylic oxidations have been observed as well as intriguing catalyst and counterion dependent directed hydrogenations.

Introduction

Diterpenoids are an important family of natural products,¹ which contain an incredible diversity of fused and bridged bicyclic architectures ranging from simple to complex structures such as the cancer chemotherapeutic agent paclitaxel² (Taxol®). Many of these diterpenoid natural products contain rare and synthetically challenging arrangement of atoms such as *anti*-Bredt olefins (paclitaxel and CP-263,114³), inside-out bridged bicyclic ring systems (ingenol⁴ and hypoxetoxin⁵) and the *bis*-axially bridged *cis*-decalin structure of vinigrol (**1**, Figure 1). The structural diversity, unusual architectures and promising biological profiles of members of this family of natural products attracted our interest. We initiated a research program dedicated to their synthesis and systematic evaluation of their

Correspondence to: Jon T. Njardarson, njardars@email.arizona.edu.

[†]Electronic Supplementary Information (ESI) available: Complete experimental, characterization and spectral data for all new compounds See DOI: 10.1039/b000000x/

biological capabilities enabled by the power of diverted total synthesis.⁶ To date we have synthesized an atropisomer of hypostoxide,⁷ the core of platensimycin⁸ and several members of a labdane diterpenoid family.⁹ In this article we present the full extent of our efforts, which resulted in a successful total synthesis of vinigrol.¹⁰

Vinigrol's unique structure, which is displayed using four different perspectives in Figure 1, was first reported in 1987.¹¹ Like Taxol®, it contains a similar [5.3.1]-bicyclic core except with an additional fused six-membered ring. Perhaps a more helpful way to describe its special architecture is as a densely decorated *cis*-decalin core with a four carbon bicyclic tether bridging the two six-membered rings. Extensive evaluation of vinigrols biological profile revealed promising activities impacting targets ranging from cancer to HIV.¹² Vinigrol's unprecedented structure immediately attracted the interest of synthetic chemists from around the globe, as reflected by the numerous publications spanning two decades presenting creative and dedicated efforts by many different research groups.^{13,14} Twenty two years after its structure was disclosed, Professor Baran completed the first total synthesis of vinigrol.¹⁵ Professor Barriault has since completed a formal synthesis of vinigrol.¹⁶

Our vinigrol retrosynthesis is outlined in Figure 2. We envisioned a late stage C-C bond carbanion mediated fragmentation to form the unusual decalin bridged vinigrol ring system from protected tetracyclic precursor **2**. The functional groups (ester and an anion initiating group) needed for the fragmentation step would be constructed from methyl acetal **3**. We hoped that the challenging C8 and C9 methyl stereocenters could be installed in a substrate controlled manner in a single step by catalytically hydrogenating two exocyclic olefins, which we believed could be easily accessed from ketone **4**. A key retrosynthetic design feature was a 6-*exo*/6-*exo* ketyl radical cyclization cascade (**5**→**4**), which we hoped would not only create the tetracyclic cage, but also correctly install the C4-hydroxyl stereocenter. The second key design feature is a one pot oxidative dearomatization/Diels-Alder cycloaddition reaction (**6**→**5**). Resorcinol precursor **6** would be decorated with an electron withdrawing group (P) whose purpose is to guide the oxidative dearomatization reaction towards the allylic ether site. Oxidative dearomatization precursor **6** would be assembled from mono protected resorcinol derivative **7** and phosphonate **8**. We were convinced that this retrosynthetic outline was flexible enough to provide us with many options to address the synthetic goals presented.

Outlined in Figure 3 is the most ambitious version we proposed would be possible for the radical cyclization cascade. We envisioned that this dream cascade could be made possible using several equivalents of samarium(II) diiodide in the appropriate solvent. The aldehyde would be reduced first to a ketyl radical, which would then undergo the above discussed 6-*exo*/6-*exo* radical cyclization cascade. With the tetracyclic cage constructed the ketone would then be reduced to a ketyl anion, which would eliminate the adjacent C-O carboxylate ester¹⁷ and then undergo a second reduction, followed by elimination of methoxy and formation of a samarium enolate. The samarium enolate would then be primed for a perfect *retro*-Michael fragmentation reaction to form the vinigrol core. Thus, in this one pot samarium mediated cascade, two C-C bonds would be formed and two C-O bonds and one C-C bond would be broken.

The tetracyclic core (Figure 4) is a key intermediate target structure, whose shape we planned to leverage to install the C4, C8, C9 and C12 stereocenters. We were confident that the cyclization cascade plans could be realized. Not only because the target rings are of optimal size (six membered), and the cyclization modes are ideal (6-*exo* only), but because the target tetracyclic core provides us with many options to assemble it. For example, a cyclization could be initiated from the front or back and the same vinyl iodide precursor could serve as either an initiating site for a radical or a palladium cyclization cascades.

The following schemes detail the evolution of our synthetic route, with discussion of the obstacles we have faced and how they were overcome to complete the total synthesis of vinigrol.

Result and Discussion

Summarized in Scheme 1 are our earlier cyclization attempts to build the tetracyclic cage.¹⁸ In all cases, the central oxidative dearomatization/Diels-Alder cycloaddition cascade proceeded as expected to deliver the radical cyclization precursors (**9**, **12** and **15**). Attempts to convert aldehyde **9** into tetracyclic cage structure **11**, and realize key elements of the cascade dream presented in Figure 3, failed to form **11** and only afforded cyclohexanol **10**. We were delighted to learn that as proposed the 6-*exo* ketyl radical cyclization formed the C4-hydroxyl stereocenter with the correct configuration needed for the vinigrol synthesis. Unfortunately, in this “front-to-back” cyclization attempt the intermediate radical reduced faster than it could undergo a second cyclization. Taking advantage of the flexibility of our synthetic route, we synthesized a second substrate (**12**), which we believed would provide the intermediate radical with a better chance of undergoing the second cyclization. We speculated that this new “back-to-front” cyclization substrate had a better shot due to the fact that the starting vinyl radical would form a *tri*-substituted *endo*-cyclic olefin, thus generating an initial six-membered ring containing two sp²-hybridized carbon, compared to a ring containing only sp³-hybridized carbons as in the case of **10**. This difference in hybridization would create more room for the second cyclization to proceed. Furthermore, we also changed the second radical acceptor from a terminal olefin to a terminal alkyne thus creating even more room for the second cyclization to succeed. Despite these significant structural changes, vinyl iodide **12** failed to form tetracyclic cage **14** and only formed *mono*-cyclization product **13**. We then turned to a stepwise solution wherein a radical *mono*-cyclization was followed by a ring closing metathesis reaction. Vinyl iodide **15** was cyclized to diketone **16**, which was then subjected to a double Petersen olefination. The resulting tetraene (**17**) was then successfully cyclized to tetracycle **18** using the Hoveyda-Grubbs second generation catalyst¹⁹ in the presence of benzoquinone²⁰ to suppress unwanted olefin isomerization.

Encouraged by the rapid and successful assembly of tetracycle **18**, we set out to synthesize a more synthetically attractive substrate containing the C16-hydroxy group instead of an undesired methylene carbon at C4 (Scheme 2). Towards that end, cuprate addition to propargylic alcohol **20** afforded diene **21** as a single olefin isomer, which was then protected to afford known allyl methyl ether **22**.²¹ Iododesilylation (**23**) followed by selective dihydroxylation and oxidative cleavage of the more electron rich olefin afforded aldehyde

25. Wittig homologation and reduction of the resulting enoate (**26**) yielded allylic alcohol **27**. Oxidative dearomatization of commercially available symmetrical pyrogallol derivative **28** in the presence of excess **27** produced cycloadduct **29** in modest yield. Use of hexafluoro-isopropanol (HFIP) as co-solvent in this reaction is critical for successful trapping of the intermediate cyclic pentadienyl cation with alcohol **27** followed by *in situ* intramolecular Diels-Alder cycloaddition. With **29** in hand we were ready to subject it to the sequence that was so successful in converting **15** to tetracyclic cage **18**. We were surprised and disappointed to learn that none of the desired cyclization product (**35**) was formed. The initially formed radical (**30**) took an unexpected 1,7-hydrogen abstraction pathway (**31**) followed by a 5-*exo* cyclization to form **32** and intermediate **33**, which then underwent a second cyclization to **34**.

Undaunted by this temporary setback, we decided to take advantage of the synthetic flexibility our tetracyclic cage presented us with (Figure 4). We decided to change the cyclization mode from “front-to-back” (Scheme 2) to “back-to-front” (Scheme 3), and to employ a substrate (**43**) that would be structurally less likely to undergo any unwanted allylic abstractions, and instead, only form desired product **48**. With **48** in hand, our hope was to subject the aldehyde **49** to a simple intramolecular condensation reaction to form tetracyclic cage **50**, which we believed contained all of the necessary functionalities to be advanced to vinigrol.

Our synthesis commenced by a Horner-Wadsworth-Emmons union between known phosphonate **36**¹⁸ and known aldehyde **37**.²² Dibal reduction of **38** afforded **39**, which was then attached to dearomatization precursor fragment **40**²³ using a Mitsunobu reaction. Our hope was that by connecting the allylic alcohol fragment **39** to the aromatic group there would be no need to use excess alcohol or worry about the efficiency of the trapping of the reactive intermediate, which had plagued formation of **29** earlier. The role of the benzoate group was not only to protect what would eventually become the C8a alcohol, but also to guide the trapping of the dearomatization intermediate with methanol towards the allylic ether site. We were gratified to learn that this design logic was indeed feasible, affording bicyclic product **42** in much higher yield than **29**. Enal **42** turned out to be a poor radical cyclization substrate. Therefore we decided to reduce the aldehyde to an alcohol (**43**). This time, the expected radical cyclization did indeed take place as planned. The only problem was that instead of getting reduced from outside the cage, as **15** had done, radical intermediate **44** was partially reduced to the other epimer (**45**). The bulk of the material underwent an unexpected 1,6-hydrogen abstraction (**46**) followed by a 6-*exo-trig* radical cyclization to form hemiacetal **47** and none of the desired ketone **48**.

Before giving up on the radicals we decided to evaluate one more substrate variation (Scheme 4). To suppress the competing intramolecular hydrogen abstraction pathway, we substituted the propionitrile fragment from Scheme 3 with a TBS-protected methylene alcohol (**56**). Towards that end, we devised a scalable one pot synthesis of enoate **52** from allylic bromide **51**.²⁴ Mitsunobu reaction with catechol **40** selectively functionalized the more activated phenol. Allylic ether **54** underwent the oxidative dearomatization/intramolecular Diels-Alder cycloaddition reaction to form **55**. Luche reduction then afforded

radical cyclization precursor **56**. Treatment of **56** with standard radical cyclization conditions did indeed result in a successful cyclization. Unfortunately, although for this substrate an allylic abstraction pathway was not feasible, we did not get any of the desired product, but instead only **57**, resulting from reduction of the intermediate radical from inside the cage. We felt that this situation could perhaps be salvaged by creating a substrate (**58**) that would not be limited by this unfavorable reduction scenario and would instead allow us to pursue alternate reduction approaches. Olefination of aldehyde **55** proceeded smoothly, affording diene ester **58**. Our hope was that **58** would cyclize to form **62**, which could then be advanced to highly functionalized tetracyclic cage products such as **63**. Although **62** did not form, an alternate useful product (**59**) was afforded in high yield. This product, *exo*-olefin **59**, is primed for catalytic hydrogenation exploration to set the propionate ester fragment inside the cage for later condensations. Unfortunately, extensive evaluation of diverse set of hydrogenation conditions only afforded ester **60**, which has the incorrect propionate ester epimer. The only silver lining was the confirmation of our substrate controlled hydrogenation thesis to install the C9-methyl group with the correct stereochemistry. We also evaluated bases in attempt to set the correct stereochemistry for the tether, but again, only the undesired epimer (**61**) was formed and none of **62**.

Unable to get the radicals to cyclize to products that we could advance towards vinigrol we turned our focus to palladium cyclizations (Scheme 5). As discussed earlier (Figure 4), many of our radical cyclization substrates can also serve as palladium cyclization substrates. The advantage of a palladium approach over a radical cyclization approach is that the bond forming is mechanistically controlled (initial *syn*-palladation sets the desired bond relationship) compared to the radicals, which have other pathway choices, such as unwanted reduction and hydrogen abstraction pathways. Of course, when sterics are considered, the radicals are much “smaller” than the palladium intermediates and the question we were most concerned about was whether palladium could operate in such close quarters. We decided to evaluate two complementary approaches. The first would involve an initial 6-*exo-trig* Heck cyclization (**64**→**65**) followed by an intermolecular Stille cross-coupling between hindered palladium intermediate **65** and stannane partner, such as **59**. The second scenario is reminiscent of key parts of our dream sequence (Figure 3), wherein a tandem 6-*exo* cyclizations was envisioned to stitch up the tetracyclic cage in one swoop. In this case, we plan to evaluate the palladium catalyzed conversion of **67** to **69**.

Our route towards the first palladium cyclization test substrate (**77**) is shown in Scheme 6. Enoate **70** was made in one pot from **51** and then reduced to allylic alcohol **71**. Phenol **72** was used for the Mitsunobu coupling. Selective derivatization of pyrogallol or simply pyrogallol precursors failed to provide reliable and efficient access to **76**, which is why pyrogallol surrogate **72**²⁵ was employed. Reduction of **73** afforded resorcinol derivative **74**. Our next task was to derivatize the phenol with an electron withdrawing group whose primary purpose would be to direct the oxidative dearomatization reaction and to tame the resulting enol ether moiety so that the intramolecular Diels-Alder cycloaddition could proceed. Earlier (**9**, **12**, **41** and **54**) we had used either a sulfonamide or a benzoate for this purpose. Unfortunately these groups did not survive or drastically impeded the Dakin oxidation needed to form the oxidative dearomatization precursor. To solve this we needed

an electron withdrawing group that was more robust, smaller and slightly less deactivating. We chose a trifluoroethyl group for this purpose (**75**). Dakin oxidation of **75** proceeded fantastically well when boronic acid²⁶ was used as an additive (**76**). The proposed oxidative dearomatization/Diels-Alder cycloaddition cascade proceeded favorably to form desired product **77** using trifluoroethyl ether as a deactivating group.

With vinyl iodide **77** in hand we were now in a position to test the first palladium cyclization hypothesis (Scheme 7). We were delighted to learn that upon treatment with vinyl tributylstannane and a palladium(0) catalyst, **77** was converted in high yield to desired diene product **79**. Interestingly, when this reaction was done with a stoichiometric amount of palladium we could isolate and characterize rare palladium intermediate **78**,²⁷ which could then be treated with vinyl tributylstannane to form **79**. More functionalized stannanes **80** and **82** also participated in this palladium cascade in partnership with **77** to form **81** and **83**, respectively.

Following a successful execution of the proposed palladium cascade, we decided next to tackle olefination of the C8-ketone (**84**, Scheme 8). For this task we chose to employ ketone **83**. We were hopeful that this could be accomplished in a single step as we had done for ketone **16** (Scheme 1) using a Peterson olefination protocol. We were not surprised to learn that standard Wittig and Julia olefination type processes failed to convert **83** to **84** as this was a lesson we had also learned for **16**. We were hopeful that the Peterson approach would work. Unfortunately, the slight structural change from a methyl-(**16**) to a trifluoroethyl-(**83**) protected C8a-alcohol was enough to block this olefination approach. We reasoned that a smaller nucleophile was needed to address this challenge, and we turned our attention to addition of a methyl group with the goal of dehydrating the resulting tertiary alcohol (**85**). Addition of a methyl Grignard reagent to **83** was successful, but resulted in the formation of a poor epimeric mixture of **85**. This in theory should be inconsequential for the following step(s), but we soon learned that it was easier to further functionalize or activate *endo*-epimer **85** than the *exo*-epimer of **85**. This temporary obstacle was solved by performing the Grignard addition in the presence of magnesium bromide,²⁸ which resulted in the exclusive formation of **85**. Direct dehydrations to form **84** from **85** were low yielding and inconsistent. We solved this dehydration problem by derivatizing **85** as a xanthate (**86**) and then subjecting it to a thermal Chugaev elimination to form triene **84**. Xanthate **86** provided us with an opportunity to set the C8-methyl stereocenter using radical reduction protocols. We evaluated several initiators and hydride sources. Although the reduction of the xanthate proceeded in high yield, the epimeric C8-mixture was in all cases highly unfavorable, with the undesired epimer (**87**) being the major one. To further complicate things, low level calculations and epimerization studies of the ketone resulting from opening of the acetals of **87** and **88** revealed that epimer **87** was the thermodynamically favored one.

We constructed triene **84** in hopes that we could form **91**, wherein in one pot three double bonds would be reduced and two benzyl groups cleaved and in doing so installing the critical methyl stereocenters C8 and C9. Using high pressure and a palladium catalyst we could indeed reduce everything we wanted to in one pot. The only problem was that the C8 olefin reduction resulted in the formation of the incorrect methyl epimer (**90**). This presented

us with a major obstacle, as clearly the tetracyclic shape was resisting functionalization as evident from our reduction and epimerization attempts. We wondered whether it would be possible to use the ethers of the adjacent acetal to direct the hydrogenation of the C8-exocyclic olefin. For this to be successful, the catalyst would need to preferentially bind to the furanyl ether over the methyl ether. It was not clear *a priori* if a catalyst directed reaction could even be accomplished in such a sterically congested setting and if any selectivity could be expected. Undeterred by these uncertainties, we set out to evaluate this approach. After extensive experimentation we found an excellent solution in the form of Pfaltz's²⁹ version of Crabtree's catalyst.³⁰ Using this catalyst and high pressure of hydrogen, we were able to convert triene **84** to **89** with complete C8-selectivity.

With **89** in hand, we set out to complete a synthesis of the tetracyclic cage and further advance towards vinigrol (Scheme 9). Exhaustive reduction of **89** in the presence of palladium on carbon and high pressure of hydrogen reduced the remaining olefin and cleaved the benzyl protecting groups (**91**). As demonstrated earlier for reduction of **59** and **84**, the C9-methyl stereocenter of **91** was predictably set using substrate control. Both alcohols were then converted to aldehydes (**92**) and then subjected to a condensation reaction mediated by dibenzyl ammonium trifluoroacetate³¹ to stitch up the tetracyclic cage (**93**). With this exciting milestone behind us, we set out to install the C4-hydroxyl group (**95**), the last remaining challenge before unraveling the vinigrol core via a fragmentation. Unfortunately, all attempts to access **95** from **93** or **94** in one step or many using directed or non-directed strategies met with failure.

The failure of forming **95** could be contributed to a sterically congested system, wherein the six-membered ring that needs to be functionalized is permanently locked in a boat conformation with the C8a-protected hydroxyl group in axial position thus blocking approach of reagents. Our extensive explorations provided us with a key clue when we learned that a directed epoxidation of **94** (not non-directed) was possible. Although this product could not be advanced we used these insights to guide our next strategic decision, which was to target the *tri*-substituted olefin isomerized variant of **94**. We were confident that this isomer could also be epoxidized, thus installing the C4-hydroxyl stereocenter directly. In order to quickly put this hypothesis to the test, we first tried to catalytically isomerize the olefin of **94**. Unfortunately, all such attempts failed. We therefore set out to execute our next blueprint.

Inspired by the palladium cascade cyclization success of vinyl iodide **77**, we decided that this would be a perfect opportunity to test the double Heck cyclization cascade³² outlined in Scheme 5. Towards that end, we set out to synthesize the requisite palladium cyclization precursor (**103**, Scheme 10). This was accomplished using the synthetic lessons from our earlier sequences. Horner-Wadsworth olefination of aldehyde **25** with known phosphonate **96**³³ afforded enoate **97** (Scheme 10). Ester reduction, Mitsunobu coupling with **72** and reduction of the lactone afforded aldehyde **100**. Trifluoroethyl ether protection and Dakin oxidation proceeded uneventfully. Oxidative dearomatization of phenol **102** then afforded palladium cyclization precursor **103**. We were delighted to learn that our proposed 6-*exo-trig*/6-*exo-trig* palladium cyclization cascade could indeed be realized (**104**) with relatively

standard reaction conditions apart from the choice of solvent (trifluorotoluene). Remarkably, the complex and compact tetracyclic core was assembled from a simple achiral acyclic precursor (**102**) in only two steps using this approach.

The conditions needed to convert **102** to **103** are worth discussing as they differ significantly from the standard reaction conditions we had applied for **41**, **54** and **76**. Key insights into our extensive optimizations of this reaction are shown in Table 1. Attempts to apply the same reaction conditions used before were met with little success, producing the desired product in only 10% yield. Changing the solvent or increasing the temperature did not provide any improvements. We suspected that the oxidant (phenyliodonium diacetate, PIDA) was slowly decomposing at higher temperatures. Using this clue, we performed the oxidative dearomatization at lower temperatures ($-78\text{ }^{\circ}\text{C}$ and $-40\text{ }^{\circ}\text{C}$), and the applied heat once we were convinced the oxidation was completed to aid the subsequent intramolecular Diels-Alder cycloaddition ($60\text{ }^{\circ}\text{C}$). These modifications resulted in marginally improved yields (15%). It is well established that trifluoroethanol can be a beneficial solvent for oxidative aromatization reactions.³⁴ When we employed trifluoroethanol, the reaction yield doubled as compared to the first run (21%). An inorganic base (NaHCO_3) was then added to the reaction in efforts to neutralize the reaction (the oxidant releases acetic acid) and suppress unwanted acid catalyzed decompositions. This modification further improved the yield to 31%. Using 2,6-lutidine instead of NaHCO_3 resulted in slightly better and consistent results. The final optimization modification, which resulted in a significant improvement in yield (53% and 64%), was to dilute the reaction. Our reason for dilution was that the intermediate reactive diene could perhaps more readily undergo self dimerizations instead of the desired intramolecular cycloaddition and that this competitive pathway could be blocked by controlling the concentration of the reaction. In a typical procedure, the starting material was dissolved in trifluoroethanol and cooled to $-40\text{ }^{\circ}\text{C}$, 2,6-lutidine was then added, followed by dropwise addition of PIDA (1.05 equivalents). After stirring at $-40\text{ }^{\circ}\text{C}$ for 1.0 h, the reaction solution was diluted with trifluoroethanol to the concentration of 0.0025 M. The solution was then heated to $60\text{ }^{\circ}\text{C}$ and stirred for 2 hours. Removal of solvent and 2,6-lutidine *in vacuo* followed by silica gel column chromatography afforded 64% yield of desired compound.

With tetracyclic structure **104** in hand we were ready to apply the cage functionalization lessons of **83** (Scheme 11). We decided to alter the sequence of events slightly, by first hydrogenating the C9-*exo*-olefin to form the C9-methyl stereocenter (**105**). Grignard addition (**106**) and the Chugaev elimination approach, which we had developed, worked and provided us with *exo*-olefin **108**.

In trying to replicate the excellent directed hydrogenation results we had achieved earlier (**84**, Scheme 8) for **108** we found that using the Pfaltz ligand system²⁸ instead of the Crabtree ligand system, while still maintaining the same counterion, to be more reproducible and reliable in accessing **109**. Using this catalyst, the C8-methyl stereocenter was selectively and efficiently installed. When the usual Crabtree catalyst is employed, the *exo*-olefin is reduced but with no selectivity.

With the C8 and C9-methyl stereocenters successfully set, we focused our attention to installing the secondary C4-hydroxyl group. We had hypothesized, based on our earlier results, that the sterically congested tri-substituted olefin could be epoxidized using a directed approach. Allylic methyl ether **109** was selectively transformed to enal **111** using selenium dioxide.³⁵ Reduction afforded allylic alcohol **112**, which we were delighted to learn underwent a smooth and selective epoxidation (**113**). With the C4-oxygen correctly installed we needed to find a way to convert epoxy alcohol **113** to allylic diol **114** and thus complete the vinigrol *pre*-fragmentation core. However, attempts to open epoxide **115** with bases or Lewis acids³⁶ proved unfruitful, leading to unreacted starting material, decomposition or unproductive reductive opening of the epoxide.

With one step conversions of **113** to **114** unsuccessful, we turned our focus to alternative solutions (Scheme 13). Towards that end, alcohol **113** was iodinated (**114**) and the iodide was treated with zinc³⁷ to open the epoxide and form **115**. Our plan was to use allylic oxidation approaches to convert **115** to **95**.

Interestingly, when *exo*-olefin **115** was treated with selenium dioxide none of the typical product (**118**) was formed, but instead a mixture of **116** and **117**. This welcomed result was one in which the steric hindrance of the cage again played a key role by interrupting the second step of the selenium oxidation resulting in a dissociation/recombination³⁸ instead of a sigmatropic rearrangement. The aldehyde and acid oxidation states are the result of selenium dioxide over oxidation. Aldehyde **116** was converted in a single step to **95**, while carboxylic acid **117** was esterified prior to being reduced to **95**.

Two types of fragmentation approaches were most appealing to us (Scheme 14), a Grob fragmentation³⁹ (two left images, **lg** = leaving group) and a samarium(II) iodide⁴⁰ mediated fragmentation (two right images). In both cases, we envisioned that the fragmentation could be initiated by a carbanion or a ketyl radical from either the top or the bottom of the tetracyclic cage. Although the most common form of samarium(II) iodide mediated C-C cleavages is that of strained ring systems, especially cyclopropane and cyclobutane systems, examples of larger ring or no-strain systems are rare in the literature.⁴¹ We believed that, in the case of vinigrol such a fragmentation is feasible due to favourable release of strain energy when the tetracyclic cage is opened.

Our first fragmentation substrate (**122**, Scheme 15) was readily prepared in few steps from acetal **109**. The most critical step of this short sequence was the opening of the acetal without epimerization of the adjacent C8-methyl stereocenters. This was accomplished using lithium tetrafluoroborate.⁴² Oxidation of the resulting alcohol (**119**), methyl Grignard addition and oxidation of secondary alcohol **121** afforded diketone fragmentation precursor **122**. Surprisingly, when **122** was subjected to the reaction conditions reported to be successful for samarium(II) diode mediated 1,4-diketone fragmentations, the expected C-C fragmentation (**124**) did not take place, instead pinacol coupling product **123** was the only product isolated. In addition to the convincing 2D-NMR characterization data, the structure of **123** was further confirmed when it was treated with lead (IV) acetate and was shown to clearly revert back to **122**. We wondered if the samarium intermediate was forming a chelate between the two ketyl moieties, and that this chelate was favoring formation of **123**. It has

been reported that HMPA⁴³ is effective in preventing or slowing down such chelates in samarium reactions. Unfortunately, in our case it did not alter the outcome.

Dissatisfied with the failure of the samarium fragmentation of diketone **122** we decided to synthesize a different 1,4-dicarbonyl fragmentation substrate that would be less likely to undergo a pinacol coupling (**126**, Scheme 16). Synthesis of ester **126** was accomplished in two standard steps from aldehyde **120**. Again, our samarium mediated fragmentation plans failed as the only isolable products from our fragmentation attempts were lactone **127** and alcohol **128**, both resulting from protonation of the desired ketyl intermediate.

The unsuccessful attempts of samarium(II) iodide mediated fragmentation prompted investigation into a more reliable Wharton fragmentation strategy, wherein compounds **133** and **135** would be the target of synthesis (Scheme 17). From the standpoint of orbital overlap most suitable for the Wharton fragmentation, mesylate **133** was considered optimal (perfect *anti*-periplanar arrangement of relevant orbitals), while mesylate **135** offered a far less satisfactory orbital overlap. Although the stereoelectronic all-*anti* arrangement is the general prerequisite for such Wharton-type fragmentations, there are a number of examples in the literature⁴⁴ of less than ideally overlapping orbital arrangements leading to successful fragmentations. Entry into this fragmentation mode was made possible by a remarkably selective and high yielding Baeyer-Villiger oxidation of aldehyde **120**. Exhaustive reduction of **129** afforded diol **130**, which could be converted to Wharton-fragmentation candidate **135** by selectively mesylating the secondary alcohol. Perfectly aligned fragmentation substrate **133** needed some additional synthetic planning. Oxidation of diol **130** afforded ketone **131**, which could be converted selectively to diol **132** by employing a directed reduction strategy in the form of the Evans-Saksena⁴⁵ reduction protocol. Mesylation of the secondary alcohol then afforded **133**. We were delighted to learn that mesylates **133** and **135** both fragmented in excellent yields to vinigrol core **134**. Although mesylate **135** takes ten times longer to complete the fragmentation reaction it more importantly shortens the synthetic sequence to **134** by two steps.

With large quantities of **134** in place we set out to convert the ketone to the appropriately configured C-12 isopropyl group (Scheme 18). We considered three main approaches: 1) olefination of the ketone followed by hydrogenation, 2) conversion of the ketone to an enol triflate, which could then be converted into a 1,3-diene ready for catalytic hydrogenations and 3) isopropyl/isopropenyl addition to the ketone followed by reduction of the resulting tertiary alcohol.

Although such strategies are well documented in the literature,⁴⁶ we quickly learned that the Wittig-type and enol triflate approaches failed for ketone **134**. We therefore focused our attention to the isopropenyl addition approach. We envisioned that the olefin could be hydrogenated and that the tertiary alcohol could be deoxygenated using xanthate or sulfonate ester reduction strategies. Alternatively, the alcohol could be dehydrated and then hydrogenated. It was not clear if these reduction approaches would set the correct C-12 stereochemistry. We were reasonably confident that the alcohol reduction approaches would afford the desired stereochemical outcome as our calculations had indicated that the natural C-12 isopropyl group configuration is more stable than its epimer.

Our C-12 isopropyl installation efforts commenced with reductive removal of the newly formed olefin (**136**, Scheme 19). We chose to first use propenyl nucleophiles for additions to the ketone as it is well known that isopropyl organometallics are notoriously problematic due to a competing hydride delivery pathway. Grignard and lithium additions failed, but the corresponding cerium vinyl reagent worked excellently.⁴⁷ In our attempts to functionalize the resulting tertiary allylic alcohol as a xanthate, acetate or a mesylate is where we ran into a major unprecedented obstacle. Regardless of base or conditions we employed (large, small, strong or weak base using low or high temperatures in a range of solvents) an unwanted facile fragmentation took place. This is the first reported example of a Grob fragmentation wherein a trifluoroethyl ether serves the role of a leaving group. We decided to instead explore if direct dehydrations of the tertiary alcohol would allow us to navigate around this serious obstacle. Towards that end we changed the cerium nucleophile to the anion of ethyl vinyl ether, which following addition and *in situ* delicately controlled hydrolysis afforded ketone **137**. After much experimentation we finally learned that Burgess reagent⁴⁸ could convert **137** to enone **139**, without falling prey to the competing fragmentation pathway.

With this major obstacle behind us, we turned our attention to the reduction of the enone double bond, with the hope of forming methyl ketone **140** preferentially over its epimer (**141**). We first explored conjugate reduction approaches using either Selectrides or copper hydrides. Both approaches were unsuccessful, affording either a 1,2-reduction or a complex mixture of products. When typical palladium catalyzed conditions (Pd/C) were employed, the enone olefin was indeed reduced but undesired ketone epimer **141** was the major product. We were gratified to learn, which was also in agreement with our calculations, that epimer **141** could be isomerized with base to desired product **140**. This approach was unsatisfactory due to the fact that these hydrogenation conditions also generated some unidentified byproducts and that the reaction was found to be irreproducible. Although the reason for this was unclear, we speculated that the slightly acidic surface of the “neutral” catalyst was resulting in the partial decomposition of the vinigrol framework. To alleviate these problems, we decided to perform the hydrogenation in the presence of potassium hydroxide⁴⁹ with the hope that any unwanted acid catalyzed reactions would be suppressed and that an *in situ* epimerization would take place mediated by the base (KOH). This strategy worked wonderfully and ensured excellent and selective conversion of **139** to **140**. The isopropyl C-12 stereocenter of vinigrol was then completed using a standard olefination/reduction strategy (**143**).

With post-fragmentation allylic ether **143** in hand we set out to test if the chemistry we had developed for converting **109** to **95** (Schemes 12 and 13) could also be realized for this substrate. Selenium oxidation and DIBAL reductions proceeded uneventfully, affording allylic alcohol **145**. We were pleased to learn that the critical directed epoxidation step responsible for incorporating the C3-oxidation state with correct configuration also worked for **145**, as did the iodination step. We found the zinc mediated epoxy ring opening of **147** to be more challenging than for **114**, but by using sonication⁵⁰ the reaction proceeded smoothly to afford *exo*-olefin **148**. The outcome of the selenium oxidation for **148** also differed significantly from that of tetracyclic cage compound **115**. Gratifyingly, the second step of

the mechanism of the selenium oxidation was again interrupted, thus providing us directly with the desired tri-substituted olefin.

While oxidation of **115** afforded enal **116** and conjugated acid **117**, none such products were observed for **148**. Instead, the different conformation of the post-fragmentation core resulted in trapping of the selenium intermediate with the C4-hydroxyl group and formation of stable selenium heterocycle **149**. We were now confronted with oxidizing the C-16 selenium bond to a primary hydroxyl group (**150**). Based on limited literature on this subject, it was suggested that selenonic acids could be oxidized to selenonic acids by sodium periodate⁵¹ or dimethyldioxirane (DMDO)⁵² and then displaced by a nucleophile, such as I^- or H_2O . We wondered if hydrogen peroxide could serve the role of both oxidant and nucleophile in converting **149** to **150**, which in turn would make it possible to perform the oxidation of **148** to **150** in one pot as these oxidizing agents are compatible.⁵³ This approach worked well, affording desired diol **150**.

With the installation of the C4-hydroxyl group behind us, the final obstacle of the total synthesis of vinigrol we faced was the cleavage of the trifluoroethyl group. First, it is worth noting that a trifluoroethyl group has never been used as a protecting group in synthesis. With very few scattered examples of this rather stable motif being explored in the literature, deprotection conditions that were compatible with the rest of the vinigrol architecture were sought. Several strategies were investigated (Scheme 21). It is reported that trifluoroethyl ethers can be converted to base-labile esters by trifluoroacetic acid.⁵⁴ Vinigrol's susceptibility to acid obviously precluded this harsh approach. A reductive approach using sodium naphthalene⁵⁵ as a reducing agent only resulted in unreacted starting material (**150**). It is also known that trifluoroethyl ethers can be converted to acetylenic esters using alkyllithium reagents,⁵⁶ via a difluorovinyl lithium intermediate. This is especially interesting to us because in Baran's approach to vinigrol,¹⁵ he demonstrated in the final step that vinigrol was compatible with strong bases such as *n*-BuLi. We were curious to learn what product would result if **150** was submitted to strong bases. For example, if a difluorovinyl ether was obtained, it could potentially be cleaved under oxidative conditions. Alternatively, if the acetylenic ether shown was obtained, it could be easily hydrolyzed and cleaved. The difluorovinyl ether could be deprotonated again and trapped with an electrophilic oxygen reagent en route to vinigrol.

To evaluate the feasibility of these plans, test compound **91** was treated with large excess of *tert*-butyl lithium in diethyl ether at $-40\text{ }^{\circ}\text{C}$ (Scheme 4.13). To our delight, acetylenic ester **151** was obtained, albeit in poor yield (31%). Brief and careful exposure of **151** to acid then afforded ester **152**, which was reduced to free alcohol **153**. Armed with these promising, but far from ideal results we decided to test it on protected vinigrol (**150**).

Unfortunately, when we applied the alkyl lithium conditions used for **91** to **150**, only small amounts of difluorovinyl ether **154** were formed along with extensive decomposition of starting material. All attempts to form and trap the difluorovinyl ether anion with electrophilic oxygen reagents such as molecular oxygen,⁵⁷ 2-sulfonyloxaziridine (Davis's oxiziridine),⁵⁸ molybdenum peroxide-pyridine-hexamethylphosphoramide (MoOPH),⁵⁹ and *bis*(trimethylsilyl)peroxide (TMSOOTMS)⁶⁰ also failed. We therefore turned our attention

towards selective formation of **154** (Scheme 22). This could be accomplished by using LDA instead of alkyl lithium bases. We hypothesized that the vinyl enol ether could be oxidatively cleaved selectively over the tri-substituted olefin, which we had shown so many times to be resistant to reductions and oxidations because of its steric nature. Osmium tetroxide⁶¹ satisfied our criteria and was shown to selectively oxidize **154**. Interestingly, the intermediate osmate ester (**155**) was surprisingly stable and needed extensive exposure to a reductive workup conditions to afford vinigrol (**1**).

Conclusion

This article describes the synthetic journey we took that eventually resulted in a successful total synthesis of vinigrol. Although our route evolved significantly over time with respect to the exact nature of reaction sequences, its fundamental retrosynthetic design principles (oxidative dearomatization/Diels-Alder cycloaddition, 6-*exo*/6-*exo* cyclization cascade, tetracyclic cage substrate control and fragmentation) have remained the same. Many useful lessons and observations can be taken from our journey, which are broadly impactful. For example, we demonstrated for the first time the usefulness of a trifluoroethyl group as both an oxygen protecting group and a valuable directing group for oxidative dearomatization reactions as well as role a leaving group in a Grob fragmentation. We revealed intriguing radical as well as uncommon selenium oxidation behavior in rigid and dense architectural frameworks. Intriguing examples of substrate controlled and functional group directed hydrogenations are particularly noteworthy. Our synthetic explorations showcase the power and reliability of the oxidative dearomatization/Diels-Alder cascade in rapidly building molecular complexity, and it emphasizes the future value in developing a robust and predictable asymmetric oxidative dearomatization protocol for converting stable aromatic building blocks into reactive valuable chiral products with many available reaction modes.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the NIH-NIGMS (Ro1 GM086584) for generous support of this program.

References

1. For examples of recently isolated diterpenoids, consults: Hanson JR. Nat Prod Rep. 2012; 29:890–898. [PubMed: 22695982] Hanson JR. Nat Prod Rep. 2011; 28:1755–1772. [PubMed: 21713271] Hanson JR. Nat Prod Rep. 2009; 26:1156–1171. [PubMed: 19693413] Hanson JR. Nat Prod Rep. 2007; 24:1332–1341. [PubMed: 18033582] and earlier reports in this series
2. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. J Am Chem Soc. 1971; 93:2325–2327. [PubMed: 5553076]
3. (a) Dabrah TT, Harwood HJ, Huang LH, Jankovich ND, Kaneko T, Li JC, Lindsey S, Moshier PM, Subashi TA, Therrien M, Watts PC. J Antibiot. 1997; 50:1–7. [PubMed: 9066758] (b) Dabrah TT, Kaneko T, Massefski W Jr, Whipple EB. J Am Chem Soc. 1997; 119:1594–1598.
4. Zechmeister K, Brandl F, Hoppe W, Hecker E, Opferkuch HJ, Adolf WW. Tetrahedron Lett. 1970; 47:4075–4078.
5. Adesomoju AA, Okogun JI, Cava MP, Carroll PJ. Heterocycles. 1983; 20:2125–2128.

6. Njardarson JT, Gaul C, Shan D, Huang XY, Danishefsky SJ. *J Am Chem Soc.* 2004; 126:1038–1040. [PubMed: 14746469]
7. McGrath NA, Lee CA, Araki H, Brichacek M, Njardarson JT. *Chem Int Ed Angew.* 2008; 47:9450–9453.
8. McGrath NA, Bartlett ES, Sittihan S, Njardarson JT. *Angew Chem Int Ed.* 2009; 48:8543–8546.
9. Mack DJ, Njardarson JT. *Angew Chem Int Ed.* 2013; 52:1543–1547.
10. Yang Q, Njardarson JT, Draghici C, Li F. *Angew Chem Int Ed.* 2013; 52:8648–8651.
11. Uchida I, Ando T, Fukami N, Yoshida K, Hashimoto M, Tada T, Koda S, Morimoto Y. *J Org Chem.* 1987; 52:5292–5293.
12. a) Ando T, Tsurumi Y, Ohata N, Uchida I, Yoshida K, Okahura M. *J Antibiot.* 1988; 41:25–30. [PubMed: 3346190] b) Ando T, Yoshida K, Okahura M. *J Antibiot.* 1998; 41:31–35. [PubMed: 2831182] c) Norris, DB.; Depledge, P.; Jackson, AP. PCT Int Appl WO. 9107 953. 1991. d) Nakajima, H.; Yamamoto, N.; Kaizu, T.; Kino, T. Jpn Kokai Tokkyo Koho JP. 07206668. 1995. e) Keane, JT. PCT Int Appl WO. 20011000229. 2001. f) Onodera, H.; Ichimura, M.; Sakurada, K.; Kawabata, A.; Ota, T. PCT Int Appl WO. 2006077954. 2006. g) Onodera, H.; Ichimura, M.; Sakurada, K.; Kawabata, A.; Ota, T. PCT Int Appl WO. 2006077954.
13. a) Devaux JF, Hanna I, Lallemand JY. *J Org Chem.* 1993; 58:2349–2350. b) Devaux JF, Hanna I, Fraisse P, Lallemand JY. *Tetrahedron Lett.* 1995; 36:9471–9474. c) Devaux JF, Hanna I, Lallemand JY, Prange T. *J Chem Res Synth.* 1996:32–33. d) Mehta G, Reddy KS. *Synlett.* 1996:625–627. e) Kito M, Sakai T, Haruta N, Shirahama H, Matsuda F. *Synlett.* 1996:1057–1060. f) Devaux JF, Hanna I, Lallemand JY. *J Org Chem.* 1997; 62:5062–5068. g) Kito M, Sakai T, Shirahama H, Miyashita M, Matsuda F. *Synlett.* 1997:219–220. h) Matsuda F, Sakai T, Okada N, Miyashita M. *Tetrahedron Lett.* 1998; 39:863–864. i) Matsuda F, Kito M, Sakai T, Okada N, Miyashita M, Shirahama H. *Tetrahedron.* 1999; 55:14369–14380. j) Gentric L, Hanna I, Ricard L. *Org Lett.* 2003; 5:1139–1142. [PubMed: 12659593] k) Gentric L, Hanna I, Huboux A, Zaghdoudi R. *Org Lett.* 2003; 5:3631–3634. [PubMed: 14507190] l) Paquette LA, Guevel R, Sakamoto S, Kim IH, Crawford J. *J Org Chem.* 2003; 68:6096–6107. [PubMed: 12895037] m) Morency L, Barriault L. *Tetrahedron Lett.* 2004; 45:6105–6107. n) Paquette LA, Efremov I, Liu Z. *J Org Chem.* 2005; 70:505–509. [PubMed: 15651793] o) Paquette LA, Efremov I. *J Org Chem.* 2005; 70:510–513. [PubMed: 15651794] p) Paquette LA, Liu Z, Efremov I. *J Org Chem.* 2005; 70:514–518. [PubMed: 15651795] q) Morency L, Barriault L. *J Org Chem.* 2005; 70:8841–8853. [PubMed: 16238317] r) Grise CM, Tessier G, Barriault L. *Org Lett.* 2007; 9:1545–1548. [PubMed: 17362025] s) Souweha MS, Enright GD, Fallis AG. *Org Lett.* 2007; 9:5163–5166. [PubMed: 17999510] t) Maimone TJ, Voica AF, Baran PS. *Angew Chem Int Ed.* 2008; 47:3054–3056.
14. The various synthetic approaches towards vinigrol have been reviewed recently: Tessier G, Barriault L. *Org Prep Proc Int.* 2007; 37:313–353. Harmata M, Calkins NL. *Chemtracts.* 2009; 22:205–209. Lu JY, Hall DG. *Angew Chem Int Ed.* 2010; 49:2286–2288. Hutters AD, Garg NK. *Chem Eur J.* 2010; 16:8586–8595. [PubMed: 20602369]
15. Maimone TJ, Shi J, Ashida S, Baran PS. *J Am Chem Soc.* 2009; 131:17066–17067. [PubMed: 19877628]
16. Poulin J, Grise-Bard CM, Barriault L. *Angew Chem Int Ed.* 2012; 51:2111–2114.
17. Hsu DS, Liao CC. *Org Lett.* 2007; 9:4563–4565. [PubMed: 17902684]
18. Morton JGM, Draghici C, Kwon LD, Njardarson JT. *Org Lett.* 2009; 11:4492–4495. [PubMed: 19728692] For our initial explorations, consults: Morton JGM, Kwon LD, Freeman J, Njardarson JT. *Tetrahedron Lett.* 2009; 50:1684–1686. Morton JGM, Kwon LD, Freeman J, Njardarson JT. *Synlett.* 2009:23–27.
19. Kingsbury JS, Harrity JPA, Bonitatebus PJ, Hoveyda A. *J Am Chem Soc.* 1999; 121:791–799.
20. Hong SH, Sanders DP, Lee CW, Grubbs RH. *J Am Chem Soc.* 2005; 127:17160–17161. [PubMed: 16332044]
21. a) Labaudiniere L, Hanaizi J, Normant JF. *J Org Chem.* 1992; 57:6903–6908. b) Duboudin JG, Jousseau BJ. *J Organomet Chem.* 1979; 168:1–11.
22. Shrestha-Dawadi PB, Lugtenburg J. *Eur J Org Chem.* 2003:4654–4663.

23. Mills SJ, Dozol H, Vandeput F, Backers K, Woodman T, Erneux C, Spiess B, Potter BVL. *ChemBioChem*. 2006; 7:1696–1706. [PubMed: 16964627]
24. Paquette LA, Hormuth S, Lovely CJ. *J Org Chem*. 1995; 60:4813–4821.
25. Hadfield A, Schweitzer H, Trova MP, Green K. *Synth Commun*. 1994; 24:1025–1028.
26. Roy A, Reddy KR, Mohanta PK, Ila H, Junjappa H. *Synth Commun*. 1999; 29:3781–3791.
27. Li CS, Jou DC, Cheng CH. *Organometallics*. 1993; 12:3945–3954.
28. Juo WJ, Lee TH, Liu WC, Ko S, Chittimalla SK, Rao CP, Liao CC. *J Org Chem*. 2007; 72:7992–8004. [PubMed: 17850098]
29. Wustenberg B, Pfaltz A. *Adv Synth Catal*. 2008; 350:174–178.
30. Crabtree R. *Acc Chem Res*. 1979; 12:331–337.
31. a) Corey EJ, Danheiser RL, Chandrasekaran S, Siret P, Keck GE, Gras JL. *J Am Chem Soc*. 1978; 100:8031–8034. b) Snyder SA, Corey EJ. *Tetrahedron Lett*. 2006; 47:2083–2086.
32. For a review of intramolecular tandem Heck reactions, see: Link JT, Overman LE. *Metal-catalyzed Cross-coupling Reactions*. Diederich F, Stang PJ. Wiley-VCH New York 1998:231–169.
33. Petter RC, Banerjee S, England S. *J Org Chem*. 1990; 55:3088–3097.
34. Kita Y, Takada T, Gyoten M, Tohma H, Zenk MH, Eichhorn J. *J Org Chem*. 1996; 61:5857–5864.
35. Bulman PC, McCarthy TJ. *Comp Org Synth*. 1991; 7:83.
36. a) Brennan NK, Guo X, Paquette LA. *J Org Chem*. 2005; 70:732–734. [PubMed: 15651832] b) Murata S, Suzuki M, Noyori R. *J Am Chem Soc*. 1979; 101:2738–2739. c) Terao S, Shiraishiand M, Kato K. *Synthesis*. 1979; 6:467–468. d) Yasuda A, Tanaka S, Oshima K, Yamamoto H, Nozaki H. *J Am Chem Soc*. 1974; 96:6513–6514. e) Yadav JS, Shekharam T, Gadgil VR. *J Chem Soc, Chem Commun*. 1990:843–844.
37. Nicolaou KC, Duggan ME, Ladduwahetty T. *Tetrahedron Lett*. 1984; 25:2069–2072.
38. Warpehoski MA, Chabaud B, Sharpless KB. *J Org Chem*. 1982; 47:2897–2900.
39. For an excellent review of Grob fragmentations, see: Prantz K, Mulzer J. *Chem Rev*. 2010; 110:3741–3766. [PubMed: 20163188]
40. For a recent review of SmI₂ mediated fragmentations, see: Bradley D, Williams G, Blann K, Caddy J. *Org Prep Proced Int*. 2001; 33:565–602.
41. a) Haque A, Ghosh S. *J Chem Soc, Chem Commun*. 1997:2039–2040. b) Williams DBG, Blann K, Holzapfel CW. *J Chem Soc, Perkin Trans I*. 2001:219–220. c) Honda T, Naito K, Yamane S, Suzuki Y. *J Chem Soc, Chem Commun*. 1992:1218–1220.
42. Lipshutz BH, Harvey DF. *Syn Commun*. 1982; 12:267–277.
43. Hou Z, Zhang Y, Wakatsuki Y. *Bull Chem Soc Jpn*. 1997; 70:149–153.
44. a) Corey EJ, Mitra RB, Uda H. *J Am Chem Soc*. 1963; 85:362–363. b) Renneberg D, Pfander H, Leumann CJ. *J Org Chem*. 2000; 65:9069–9079. [PubMed: 11149853] c) Khripach VA, Zhabinskii VN, Fando GP, Kuchto AI, Lyakhov AS, Govorova AA, Groen MB, van der Louw J, de Groot A. *Steroids*. 2004; 69:495–499. [PubMed: 15246779]
45. a) Saksena AK, Mangiaracina P. *Tetrahedron Lett*. 1983; 24:273–276. b) Evans DA, Chapman KT. *Tetrahedron Lett*. 1986; 27:5939–5942.
46. For hydrogenation approach, see: Oppolzer W, Wylie RD. *Helv Chim Acta*. 1980; 63:1198–1203. Baldwin SW, Gawley RE. *Tetrahedron Lett*. 1975; 46:3969–3972. Gutke HJ, Oesterreich K, Spitzner D, Braun NA. *Tetrahedron*. 2001; 57:997–1003. Srikrishna A, Satyanarayana G. *Tetrahedron Lett*. 2006; 47:367–370. Karimi S. *J Nat Prod*. 2001; 64:406–410. [PubMed: 11325217] Nicolaou KC, Gray DLF, Tae J. *J Am Chem Soc*. 2004; 126:613–627. [PubMed: 14719961] For radical deoxygenation approach, see Barton DHR, McCombie SW. *J Chem Soc, Perkin Trans I*. 1975; 16:1574–1585. Wardrop DJ, Forslund RE, Landrie CL, Velter AI, Wink D, Bushan S. *Tetrahedron: Asymmetry*. 2003; 14:929–940. Dolan SC, MacMillan J. *J Chem Soc, Chem Commun*. 1985:1588–1589. Lecomte V, Stephan E, Rager MN, Jaouen G. *J Org Chem*. 2004; 69:3216–3219. [PubMed: 15104469] For reductive deoxygenation approach, see: Alesso EN, Bianchi ENDE, Finkelsztejn LM, Lantano B, Moltrasio GY, Aguirre JM. *Tetrahedron Lett*. 1995; 36:3299–3302. Tedesco R, Fiaschi R, Napolitano E. *J Org Chem*. 1995; 60:5316–5318. For palladium-mediated deoxygenation approach, see: Manddai T, Suzuki S, Murakami T, Fujita M, Kawada M, Tsuji J. *Tetrahedron Lett*. 1992; 33:2987–2990. Zhang Q, Porco JA. *Org Lett*. 2012;

- 14:1796–1799. [PubMed: 22449198] For triflate approach, see: Comins D, Dehghani A. *Tetrahedron Lett.* 1992; 33:6299–6302. Ibuka T, Aoyagi T, Yoneda F. *J Chem Soc, Chem Commun.* 1985:1452–1454. Shirakawa E, Imazaki Y, Hayashi T. *Chem Lett.* 2008; 37:654–655. Han XJ, Stoltz BM, Corey EJ. *J Am Chem Soc.* 1999; 121:7600–7605.
47. a) Imamoto M, Sugiura Y, Takiyama N. *Tetrahedron Lett.* 1984; 25:4233–4236. b) Braish TF, Saddler JC, Fuchs PL. *J Org Chem.* 1988; 53:3647–3658.
48. Atkins GM, Burgess EM. *J Am Chem Soc.* 1968; 90:4744–4745.
49. Wilds AL, Johnson JA, Sutton RE. *J Am Chem Soc.* 1950; 72:5524–5529.
50. Sarandeses LA, Mourino A, Luche JL. *J Chem Soc, Chem Commun.* 1991:818–820.
51. Tenn WJ, Conley BL, Hövelmann CH, Ahlquist M, Nielsen RJ, Ess DH, Oxgaard J, Bischof SM, Goddard WA, Periana RA. *J Am Chem Soc.* 2009; 131:2466–2468. [PubMed: 19161305]
52. Abdo M, Knapp S. *J Am Chem Soc.* 2008; 130:9234–9235. [PubMed: 18576651]
53. a) Francis MJ, Grant PK, Low KS, Weavers RT. *Tetrahedron.* 1976; 32:95–101. b) Wilson CW, Shaw PE. *J Org Chem.* 1973; 38:1684–1687.
54. Schwertfeger H, Würtele C, Serafin M, Hausmann H, Carlson RMK, Dahl JEP, Schreiner PR. *J Org Chem.* 2008; 73:7789–7792. [PubMed: 18761438]
55. a) Sargent GD. *J Am Chem Soc.* 1971; 93:5268–5269. b) Baldwin SW, Tomesch JC. *J Org Chem.* 1980; 45:1455–1462.
56. a) Nakai T, Tanaka K, Ishikawa N. *Chem Lett.* 1976:1263–1266. b) Tanaka K, Shiraishi S, Nakai T, Ishikawa N. *Tetrahedron Lett.* 1978; 19:3103–3106. c) Kocienski PJ, Snaddon TN. *Org Synth.* 2008; 85:45–52.
57. a) Wasserman HH, Lipshutz BH. *Tetrahedron Lett.* 1975; 16:1731–1734. b) Paquette LA, DeRussy DT, Pegg NA, Taylor RT, Zydowsky TM. *J Org Chem.* 1989; 54:4576–4581. c) Moller M, Husemann M, Boche G. *J Organomet Chem.* 2001; 624:47–52. d) Lubin H, Tessier A, Chaume G, Pytkowicz J, Brigaud T. *Org Lett.* 2010; 12:1496–1499. [PubMed: 20218638]
58. a) Davis FA, Wei J, Sheppard AC, Gubernick S. *Tetrahedron Lett.* 1987; 28:5115–5118. b) Davis FA, Sheppard AC. *Tetrahedron.* 1989; 45:5703–5742.
59. a) Vedejs E. *J Am Chem Soc.* 1974; 98:5944–5945. b) Milgram BC, Liao BB, Shair MD. *Org Lett.* 2011; 13:6436–6439. [PubMed: 22084899]
60. a) Taddei M, Ricci A. *Synthesis.* 1986:633–635. b) Pohmakotr M, Winotai C. *Synth Commun.* 1988; 18:2141–2146. c) Ishikawa H, Elliott GI, Velcicky J, Choi Y, Boger DL. *J Am Chem Soc.* 2006; 128:10596–10612. [PubMed: 16895428]
61. Herrmann WA, Eder SJ, Scherer W. *Angew Chem Int Ed.* 1992; 31:1345–1347.

Figure 1.
Vinigrol Structural Perspectives

Figure 2.
Njardarson Group Vinigrol Retrosynthesis

Figure 3.
Samarium(II) Diiodide Mediated Dream Cascade

Figure 4.
Tetracyclic Core – Tandem Cyclization Choices

Scheme 1.

Njardarsons Group Earlier Tetracyclic Core Attempts

Scheme 2.
Modified Front to Back Stepwise Radical Approach

Scheme 3.
Modified Back to Front Stepwise Radical Route

Scheme 4.2nd Modified Back to Front Stepwise Radical Route

Heck-Stille Cyclization/Cross-Coupling Cascade *Heck (6-exo-trig/6-exo-trig) Cyclization Cascade*

Scheme 5.
Retire Radicals – Begin Palladium Chapter

Scheme 6.
Palladium (route 1) – Oxidative Dearomatization

Scheme 7.
Palladium (route 1) – Cascade Works

Scheme 8.
Palladium (route 1) – C8-Methyl Installation

Scheme 9.
Palladium (route 1) – Tetracyclic Cage Synthesis

Scheme 10.
Palladium (route 2) – Tetracyclic Cage Synthesis

Scheme 11.
 Palladium (route 2) – C8 and C8-Methyl Groups

Scheme 12.
C4-Hydroxyl Installation Attempts

Scheme 13.
 Palladium (route 2) – Installing C4-Hydroxyl

Scheme 14.
Carbanion Mediated Fragmentation Options

Scheme 15.
Samarium Diketone Fragmentation Attempt

Scheme 16.
Samarium Keto-Ester Fragmentation Attempt

Scheme 17.
Wharton Fragmentation – Vinigrol Core

Scheme 18.
Strategies for Installing the C12-Isopropyl Group

Scheme 19.
Installation of C12-Isopropyl Group

Scheme 20.
Selenium Adventures – Installing C4-Hydroxyl

Scheme 21.
Strategies for Removing $-\text{CH}_2\text{CF}_3$ Group

Scheme 22.
Successful Synthesis – Deprotection of CH_2CF_3

Table 1

Oxidative Dearomatization Optimization Studies

solvent	Temp. ^a (°C)	base	time ^d (hours)	conc. ^b (M)	Yield
MeOH	60, 60	-	2.5, 4.0	0.01	10%
DCM	60, 60	-	2.0, 1.5	0.01	10%
toluene	60, 60	-	2.5, 4.0	0.01	6%
toluene	110, 110	-	1.5, 2.0	0.01	0%
MeOH	-78, 60	-	1.0, 3.0	0.01	15%
MeOH	-40, 60	-	1.0, 2.0	0.01	15%
CF ₃ CH ₂ OH	-40, 60	-	1.0, 2.0	0.01	21%
CF ₃ CH ₂ OH	-40, 60	NaHCO ₃	1.0, 2.0	0.01	30%
CF ₃ CH ₂ OH	-40, 60	2,6-lutidine	1.0, 2.0	0.01	35%
CF ₃ CH ₂ OH	-40, 60	2,6-lutidine	1.0, 2.0	0.005	53%
CF ₃ CH ₂ OH	-40, 60	2,6-lutidine	1.0, 2.0	0.0025	64%

^a First number refers to the temperature/addition time during addition of oxidant (PIDA) while the second number refers to the reaction temperature and time post addition of oxidant.

^b Final concentration. For large scale batches the reaction was diluted with toluene.